Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

Novo said the trial suggests the drug is safe and has a similar side effect ... potentially worth as much as $100 billion or more by the end of the decade. Novo, along with another diabetes ...

It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

Sen. Sanders claims that the CEOs of major generic drugmakers said they produce and sell Ozempic for less $100 a month.

Americans are paying more than $900 a month for popular weight-loss drugs Ozempic and Wegovy, but drugmakers want to sell ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

Promising early data from an experimental trial of a new obesity treatment pill has sent shares of Danish pharmaceutical Novo Nordisk skyrocketing ... could be worth $100 billion by 2030 ...

A study published Tuesday in The New England Journal of Medicine showed that children between the ages of six and 12 who took ...

Along with NASH, Novo Nordisk is also planning to investigate the drug's activity in chronic kidney ... with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...